286 related articles for article (PubMed ID: 23072421)
21. Photoperiodic changes in endocannabinoid levels and energetic responses to altered signalling at CB1 receptors in Siberian hamsters.
Ho JM; Smith NS; Adams SA; Bradshaw HB; Demas GE
J Neuroendocrinol; 2012 Jul; 24(7):1030-9. PubMed ID: 22420341
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats.
Mathes CM; Ferrara M; Rowland NE
Am J Physiol Regul Integr Comp Physiol; 2008 Jul; 295(1):R67-75. PubMed ID: 18448611
[TBL] [Abstract][Full Text] [Related]
23. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
[TBL] [Abstract][Full Text] [Related]
24. Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala.
Blasio A; Iemolo A; Sabino V; Petrosino S; Steardo L; Rice KC; Orlando P; Iannotti FA; Di Marzo V; Zorrilla EP; Cottone P
Neuropsychopharmacology; 2013 Nov; 38(12):2498-507. PubMed ID: 23793355
[TBL] [Abstract][Full Text] [Related]
25. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
Järbe TU; Lamb RJ; Liu Q; Makriyannis A
Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
[TBL] [Abstract][Full Text] [Related]
26. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
27. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.
Suplita RL; Eisenstein SA; Neely MH; Moise AM; Hohmann AG
Neuropharmacology; 2008 Jan; 54(1):161-71. PubMed ID: 17714742
[TBL] [Abstract][Full Text] [Related]
28. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
29. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Martín-García E; Burokas A; Martín M; Berrendero F; Rubí B; Kiesselbach C; Heyne A; Gispert JD; Millán O; Maldonado R
J Neurochem; 2010 Mar; 112(5):1338-13351. PubMed ID: 20028452
[TBL] [Abstract][Full Text] [Related]
30. Endocannabinoid signal in the gut controls dietary fat intake.
DiPatrizio NV; Astarita G; Schwartz G; Li X; Piomelli D
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12904-8. PubMed ID: 21730161
[TBL] [Abstract][Full Text] [Related]
31. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Li F; Fang Q; Liu Y; Zhao M; Li D; Wang J; Lu L
Eur J Pharmacol; 2008 Jul; 589(1-3):122-6. PubMed ID: 18534572
[TBL] [Abstract][Full Text] [Related]
33. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
[TBL] [Abstract][Full Text] [Related]
35. Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake.
Verty AN; McFarlane JR; McGregor IS; Mallet PE
Neuropharmacology; 2004 Sep; 47(4):593-603. PubMed ID: 15380376
[TBL] [Abstract][Full Text] [Related]
36. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.
Dodd GT; Mancini G; Lutz B; Luckman SM
J Neurosci; 2010 May; 30(21):7369-76. PubMed ID: 20505104
[TBL] [Abstract][Full Text] [Related]
37. Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder.
Vimalanathan A; Gidyk DC; Diwan M; Gouveia FV; Lipsman N; Giacobbe P; Nobrega JN; Hamani C
Neuropharmacology; 2020 Apr; 166():107965. PubMed ID: 31962287
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.
Kangas BD; Delatte MS; Vemuri VK; Thakur GA; Nikas SP; Subramanian KV; Shukla VG; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Mar; 344(3):561-7. PubMed ID: 23287700
[TBL] [Abstract][Full Text] [Related]
39. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
[TBL] [Abstract][Full Text] [Related]
40. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Järbe TU; LeMay BJ; Vemuri VK; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2011 Aug; 216(3):355-65. PubMed ID: 21369753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
